Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 2, 2008, Pages 463-474

  Gonzalez, Nieves ^a   Hocart, Simon J ^b   Portal Nuñez, Sergio ^c   Mantey, Samuel A ^a   Nakagawa, Tomoo ^a   Zudaire, Enrique ^c   Coy, David H ^b   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BOMBESIN RECEPTOR; BOMBESIN RECEPTOR 3; BOMBESIN RECEPTOR AGONIST; BOMBESIN[6-14]; GASTRIN RELEASING PEPTIDE RECEPTOR; GLYCINE; HISTIDINE; HORMONE RECEPTOR AFFECTING AGENT; LYSINE; PHOSPHOLIPASE C; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHIMERA; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; MOUSE; MUTAGENESIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; WILD TYPE;

3T3 CELLS; ANIMALS; BINDING SITES; BOMBESIN; CATTLE; CHO CELLS; CRICETINAE; CRICETULUS; MICE; MICE, INBRED BALB C; RECEPTORS, BOMBESIN;

EID: 38749134845     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.132332     Document Type: Article

References (40)

1. Akeson M, Sainz E, Mantey SA, Jensen RT, and Battey JF (1997) Identification of four amino acids in the gastrin-releasing peptide C receptor that are required for high affinity agonist binding. J Biol Chem 272:17405-17409.
2. Benya RV, Akeson M, Mrozinski J, Jensen RT, and Battey JF (1994) Internalization of the gastrin-releasing peptide receptor is mediated by phospholipase C-dependent and -independent processes. Mol Pharmacol 46:495-501.
3. Boyle RG, Humphries J, Mitchell T, Showell GA, Apaya R, Iijima H, Shimada H, Arai T, Ueno H, Usui Y, et al. (2005) The design of a new potent and selective ligand for the orphan bombesin receptor subtype 3 (BRS3). J Pept Sci 11:136-141.
4. Case DA, Cheatham TE III, Darden T, Gohlke H, Luo R, Merz KM Jr, Onufriev A, Simmerling C, Wang B, and Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688.
5. Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, and Laburthe M (1996) Vasoactive intestinal peptide (VIP) 1 receptor: three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucinemide. J Biol Chem 271:12795-12800.
6. Dong M, Ding XQ, Thomas SE, Gao F, Lam PC, Abagyan R, and Miller LJ (2007) Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation: use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction. Biochemistry 46:4522-4531.
7. Donohue RJ, Sainz E, Akeson M, Kroog GS, Mantey SA, Battey JF, Jensen RT, and Northrup JK (1999) An aspartate residue at the extracellular boundary of TMII, and an arginine residue at TMVII of the gastrin-releasing peptide receptor interact to facilitate heterotrimeric G protein coupling. Biochemistry 38:9366-9372.
8. Fathi Z, Benya RV, Shapira H, Jensen RT, and Battey JF (1993a) The fifth transmembrane segment of the neuromedin B receptor is critical for high affinity neuromedin B binding. J Biol Chem 268:14622-14626.
9. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, and Battey JF (1993b) BRS-3: novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 268:5979-5984.
10. Fong TM, Cascieri MA, Yu H, Bansal A, Swain C, and Strader CD (1993) Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345. Nature 362:350-353.
11. Hjorth SA, Schambye HT, Greenlee WJ, and Schwartz TW (1994) Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J Biol Chem 269:30953-30959.
12. Holtmann MH, Hadac EM, and Miller LJ (1995) Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors: studies of chimeric receptors. J Biol Chem 270:14394-14398.
13. Jensen RT, Battey JF, Spindel ER, and Benya RV (2007) International Union of Pharmacology: the bombesin receptors: nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev, in press.
14. Jensen RT and Moody TW (2006) Bombesin-related peptides and neurotensin: effects on cancer growth/proliferation and cellular signaling in cancer, in Handbook of Biologically Active Peptides (Kastin AJ ed) pp 429-434, Elsevier, Amsterdam, The Netherlands.
15. Knudsen SM, Tams JW, and Fahrenkrug J (2000) Role of second extracellular loop in the function of human vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide receptor 1 (hVPAC1R). J Mol Neurosci 14:137-146.
16. Kobayashi T, Kiriyama M, Hirata T, Hirata M, Ushikubi F, and Narumiya S (1997) Identification of domains conferring ligand binding specificity to the prostanoid receptor: studies on chimeric prostacyclin/prostaglandin D receptors. J Biol Chem 272:15154-15160.
17. Kobilka BK (2007) G protein coupled receptor structure and activation. Biochim Biophys Acta 1768:794-807.
18. Li H, Hsu P, Sachais BS, Krause JE, Leeman SE, and Boyd ND (1996) Identification of the site in the substance P (NK-1) receptor for modulation of peptide binding by sulfhydryl reagents. J Biol Chem 271:1950-1956.
19. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, and Maki RA (1997) Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 11:2048-2053.
20. Lin Y, Jian X, Lin Z, Kroog GS, Mantey S, Jensen RT, Battey J, and Northup J (2000) Two amino acids in the sixth transmembrane segment of the mouse gastrin-releasing peptide receptor are important for receptor activation. J Pharmacol Exp Ther 294:1053-1062.
21. Mantey SA, Coy DH, Entsuah LK, and Jensen RT (2004) Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3. J Pharmacol Exp Ther 310:1161-1170.
22. Mantey SA, Coy DH, Pradhan TK, Igarashi H, Rizo IM, Shen L, Hou W, Hocart SJ, and Jensen RT (2001) Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3. J Biol Chem 276:9219-9229.
23. Mantey SA, Gonzalez N, Schumann M, Pradhan TK, Shen L, Coy DH, and Jensen RT (2006) Identification of bombesin receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution, and evaluation of putative reported selective ligands. J Pharmacol Exp Ther 319:980-989.
24. Mantey SA, Weber HC, Sainz E, Akeson M, Ryan RR, Pradhan TK, Searles RP, Spindel ER, Battey JF, Coy DH, et al. (1997) Discovery of a high affinity radio-ligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates it has a unique pharmacology compared to other mammalian bombesin receptors. J Biol Chem 272:26062-26071.
25. Meng F, Taylor LP, Hoversten MT, Ueda Y, Ardati A, Reinscheid RK, Monsma FJ, Watson SJ, Civelli O, and Akil H (1996) Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J Biol Chem 271:32016-32020.
26. Nakagawa T, Hocart SJ, Schumann M, Tapia JA, Mantey SA, Coy DH, Tokita K, Katsuno T, and Jensen RT (2005) Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP). Biochem Pharmacol 69:579-593.
27. Nakamichi Y, Wada E, Aoki K, Ohara-Imaizumi M, Kikuta T, Nishiwaki C, Matsushima S, Watanabe T, Wada K, and Nagamatsu S (2004) Functions of pancreatic beta cells and adipocytes in bombesin receptor subtype-3-deficient mice. Biochem Biophys Res Commun 318:698-703.
28. Ohki-Hamazaki H, Watase K, Yamamoto K, Ogura H, Yamano M, Yamada K, Maeno H, Imaki J, Kikuyama S, Wada E, et al. (1997) Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature 390:165-169.
29. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, and Buss V (2004) The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol 342:571-583.
30. Paillasse MR, Deraeve C, de MP, Mhamdi L, Favre G, Poirot M, and Silvente-Poirot S (2006) Insights into the cholecystokinin 2 receptor binding site and processes of activation. Mol Pharmacol 70:1935-1945.
31. Porcher C, Juhem A, Peinnequin A, and Bonaz B (2005) Bombesin receptor subtype-3 is expressed by the enteric nervous system and by interstitial cells of Cajal in the rat gastrointestinal tract. Cell Tissue Res 320:21-31.
32. Pradhan TK, Katsuno T, Taylor JE, Kim SH, Ryan RR, Mantey SA, Donohue PJ, Weber HC, Sainz E, Battey JF, et al. (1998) Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol 343:275-287.
33. Ryan RR, Weber HC, Hou W, Sainz E, Mantey SA, Battey JF, Coy DH, and Jensen RT (1998) Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3. J Biol Chem 273:13613-13624.
34. Sainz E, Akeson M, Mantey SA, Jensen RT, and Battey JF (1998) Four amino acid residues are critical for high affinity binding of neuromedin B to the neuromedin B receptor. J Biol Chem 273:15927-15932.
35. Sano H, Feighner SD, Hreniuk DL, Iwaasa H, Sailer AW, Pan J, Reitman ML, Kanatani A, Howard AD, and Tan CP (2004) Characterization of the bombesin-like peptide receptor family in primates. Genomics 84:139-146.
36. Schulz S, Rocken C, and Schulz S (2006) Immunohistochemical detection of bombesin receptor subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies. Virchows Arch 449:421-427.
37. Silvente-Poirot S, Escrieut C, and Wank SA (1998) Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 54:364-371.
38. Tokita K, Hocart SJ, Katsuno T, Mantey SA, Coy DH, and Jensen RT (2001a) Tyrosine 220 in the fifth transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368. J Biol Chem 276:495-504.
39. Tokita K, Katsuno T, Hocart SJ, Coy DH, Llinares M, Martinez J, and Jensen RT (2001b) Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor. J Biol Chem 276:36652-36663.
40. Wang WW, Shahrestanifar M, Jin J, and Howells RD (1995) Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proc Natl Acad Sci U S A 92:12436-12440.